# Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

> **NCT03582475** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Bladder Small Cell Neuroendocrine Carcinoma
- Castration-Resistant Prostate Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Urethral Urothelial Carcinoma
- Prostate Carcinoma Metastatic in the Bone
- Prostate Neuroendocrine Neoplasm
- Prostate Small Cell Carcinoma
- Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8
- Stage III Prostate Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
- Stage IVA Bladder Cancer AJCC v8
- Stage IVB Bladder Cancer AJCC v8
- Ureter Small Cell Carcinoma
- Urothelial Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **DRUG:** Etoposide
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03582475
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-11
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03582475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03582475, "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03582475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*